A phase 2/3, interventional safety, pharmacokinetics, and efficacy, open-label, multi-center, single-arm study to investigate orally administered nirmatrelvir/ritonavir in non-hospitalized symptomatic pediatric participants with COVID-19 who are at risk of progression to severe disease